gabriele Buda

List of Publications by Year
in descending order

115 papers	1,477 citations	393982 19 h-index	377514 34 g-index
118 all docs	118 docs citations	118 times ranked	2743 citing authors

#	Article	IF	Citations
1	Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology, 2007, 138, 396-397.	1.2	181
2	Characteristics and outcome of therapyâ€related myeloid neoplasms: Report from the <scp>I</scp>talian network on secondary leukemias. American Journal of Hematology, 2015, 90, E80-5.	2.0	93
3	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica, 2008, 93, 398-404.	1.7	92
4	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology, 2020, 27, 1806-1815.	0.8	60
5	Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology, 2010, 89, 1133-1140.	0.8	54
6	[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, andÂMimicking Conditions. JACC: Cardiovascular Imaging, 2021, 14, 246-255.	2.3	51
7	MDR1 polymorphism influences the outcome of multiple myeloma patients. British Journal of Haematology, 2007, 137, 454-456.	1.2	45
8	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	5.8	38
9	High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naÃ¯ve lymphocytes and prevents TTV reactivation. Leukemia Research, 2018, 70, 20-24.	0.4	36
10	The CoV-2 outbreak: how hematologists could help to fight Covid-19. Pharmacological Research, 2020, 157, 104866.	3.1	36
11	Human autologous plasmaâ€derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. Journal of Orthopaedic Research, 2008, 26, 176-183.	1.2	34
12	Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications. Cellular Oncology (Dordrecht), 2020, 43, 155-176.	2.1	34
13	MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and Genomics, 2008, 18, 383-389.	0.7	30
14	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer, 2015, 136, E351-8.	2.3	30
15	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leukemia Research, 2010, 34, 184-189.	0.4	28
16	A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leukemia and Lymphoma, 2011, 52, 1942-1948.	0.6	28
17	CD45 expression in low-grade B-cell non-Hodgkin's lymphomas. Leukemia Research, 2008, 32, 263-267.	0.4	24
18	A realâ€world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematological Oncology, 2021, 39, 41-50.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Supportive Care in Cancer, 2011, 19, 1505-1510.	1.0	20
20	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leukemia Research, 2011, 35, 899-903.	0.4	20
21	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. British Journal of Haematology, 2012, 158, 805-809.	1.2	19
22	Myelomatous Meningitis Evaluated by Multiparameter Flow Cytometry : Report of a Case and Review of the Literature. Journal of Clinical and Experimental Hematopathology: JCEH, 2014, 54, 129-136.	0.3	18
23	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 555.	1.3	18
24	Piezoelectric Signals in Vascularized Bone Regeneration. Biomolecules, 2021, 11, 1731.	1.8	18
25	Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leukemia Research, 2010, 34, 1336-1339.	0.4	17
26	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
27	Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leukemia Research, 2008, 32, 988-990.	0.4	15
28	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica, 2016, 101, e196-e199.	1.7	15
29	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). International Journal of Oncology, 2011, 40, 625-38.	1.4	14
30	The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 532.	1.3	14
31	Could age modify the effect of genetic variants in IL6 and TNF-Î± genes in multiple myeloma?. Leukemia Research, 2012, 36, 594-597.	0.4	13
32	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the <scp>IMME</scp>n<scp>SE</scp> consortium. British Journal of Haematology, 2012, 157, 331-338.	1.2	13
33	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associationsâ€"An Extensive Replication of the Associations from the Candidate Gene Era. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 670-674.	1.1	13
34	Fludarabine, Bortezomib, Myocet^{Â®} and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. British Journal of Haematology, 2010, 148, 810-812.	1.2	12
35	Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. Hematological Oncology, 2013, 31, 72-78.	0.8	11
36	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	1.6	11

#	ARTICLE	IF	CITATIONS
37	CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. Acta Haematologica, 2016, 135, 11-14.	0.7	11
38	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. British Journal of Haematology, 2018, 183, 375-384.	1.2	11
39	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia and Lymphoma, 2019, 60, 1803-1811.	0.6	11
40	VDTPACEÂAs Salvage Therapy For Heavily Pretreated MM Patients. Blood, 2013, 122, 5377-5377.	0.6	11
41	NQO1*2 polymorphism and response to treatment in patients with multiple myeloma. Leukemia Research, 2007, 31, 1029-1030.	0.4	10
42	MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma. Acta Haematologica, 2009, 122, 42-45.	0.7	10
43	How to facilitate early diagnosis of CNS involvement in malignant lymphoma. Expert Review of Hematology, 2016, 9, 1081-1091.	1.0	10
44	Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer Journal, 2021, 11, 74.	2.8	10
45	Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). Leukemia Research, 2007, 31, 1765-1766.	0.4	9
46	Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. Leukemia Research, 2008, 32, 191-192.	0.4	9
47	Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Leukemia Research, 2008, 32, 49-53.	0.4	8
48	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	2.3	8
49	Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia. TH Open, 2019, 03, e64-e66.	0.7	8
50	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. Frontiers in Immunology, 2020, 11, 573156.	2.2	8
51	Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype. Acta Haematologica, 2007, 118, 27-29.	0.7	7
52	Unusual association of endometrial cancer and multiple myeloma. Gynecologic Oncology, 2008, 110, 265-266.	0.6	7
53	Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. Acta Haematologica, 2013, 129, 35-39.	0.7	7
54	Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.. Blood, 2009, 114, 109-109.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. Leukemia Research, 2008, 32, 190-191.	0.4	6
56	Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retroâ€prospective observational study. European Journal of Haematology, 2022, 109, 373-380.	1.1	6
57	Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. Leukemia Research, 2008, 32, 194-195.	0.4	5
58	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a caseâ€“control study in the context of the IMMEnSE consortium. Journal of Human Genetics, 2013, 58, 155-159.	1.1	5
59	Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. European Journal of Haematology, 2020, 104, 138-144.	1.1	5
60	A polygenic risk score for multiple myeloma risk prediction. European Journal of Human Genetics, 2022, 30, 474-479.	1.4	5
61	Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression. Medical Science Monitor, 2009, 15, CS27-29.	0.5	5
62	Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma. Melanoma Research, 2006, 16, 467-468.	0.6	4
63	Folate levels and methylation of CDKI proteins. Leukemia Research, 2007, 31, 569-570.	0.4	4
64	MDR1 modulates apoptosis in CD34+ leukemic cells. Annals of Hematology, 2008, 87, 1017-1018.	0.8	4
65	Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. Leukemia Research, 2008, 32, 192-194.	0.4	4
66	correspondence: CD23 expression in plasma cell leukaemia. British Journal of Haematology, 2010, 150, 724-725.	1.2	4
67	Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 135-137.	1.4	4
68	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. Frontiers in Medicine, 2021, 8, 712070.	1.2	4
69	The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience.. Blood, 2009, 114, 5007-5007.	0.6	4
70	Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. Annals of Hematology, 2011, 90, 1115-1116.	0.8	3
71	Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e13-e17.	0.2	3
72	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. Cancer Cell International, 2019, 19, 83.	1.8	3

#	ARTICLE	IF	CITATIONS
73	Different types of amyloid concomitantly present in the same patients. Hematology Reports, 2019, 11, 7996.	0.3	3
74	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	2.3	3
75	Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. Blood, 2011, 118, 4585-4585.	0.6	3
76	MDR1 pump: More than a drug transporter. Leukemia Research, 2008, 32, 359-360.	0.4	2
77	Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. Acta Haematologica, 2009, 122, 39-41.	0.7	2
78	PRDI-BF1 and PRDI-BF1Î² isoform expressions correlate with disease status in multiple myeloma patients. Hematology Reports, 2017, 9, 7201.	0.3	2
79	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. JACC: Case Reports, 2021, 3, 450-454.	0.3	2
80	Mesangiogenic Progenitor Cells Are Tissue Specific and Cannot Be Isolated From Adipose Tissue or Umbilical Cord Blood. Frontiers in Cell and Developmental Biology, 2021, 9, 669381.	1.8	2
81	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. Medicina (Lithuania), 2021, 57, 900.	0.8	2
82	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697.	0.6	2
83	Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma. Oncotarget, 2019, 10, 6781-6790.	0.8	2
84	Daratumumab in AL Amyloidosis: A Real-Life Experience of the â€œRTMâ€•(Regional Tuscan Myeloma) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.1	2
85	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	2
86	A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13). Leukemia Research, 2007, 31, 1599-1600.	0.4	1
87	Association of PIM gene translocation and TEL/AML1 rearrangement. Leukemia Research, 2007, 31, 1761-1762.	0.4	1
88	Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy. Cancer Genetics and Cytogenetics, 2007, 177, 166-167.	1.0	1
89	Stable low IgG levels in relapsed non-Hodgkinâ€™s lymphomas. Annals of Hematology, 2007, 86, 851-853.	0.8	1
90	Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. Leukemia Research, 2008, 32, 188-190.	0.4	1

#	ARTICLE	IF	CITATIONS
91	Primary non-Hodgkin lymphoma in the pterygopalatine fossa. A peculiar diagnosis with a minimally invasive endoscopic approach. Annals of Hematology, 2014, 93, 345-346.	0.8	1
92	Role of Yttrium-90 Ibritumomab Tiuxetan (ZevalinÂ®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkinâ€™s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen.. Blood, 2007, 110, 4498-4498.	0.6	1
93	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. Blood, 2013, 122, 4383-4383.	0.6	1
94	TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib. Blood, 2008, 112, 216-216.	0.6	1
95	Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL). Blood, 2012, 120, 1645-1645.	0.6	1
96	Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. Hematology Reports, 2022, 14, 19-23.	0.3	1
97	Folate levels in cancer: a vitamin for a new challenge. Annals of Hematology, 2007, 86, 389-389.	0.8	0
98	Other mechanisms to explain the role of reduced folate carrier in cancer. European Journal of Haematology, 2008, 80, 365-365.	1.1	0
99	Folic acid fortification and cancer risk. Lancet, The, 2008, 371, 1336.	6.3	0
100	The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation. Acta Haematologica, 2019, 141, 7-11.	0.7	0
101	Unusual concomitant smallâ€•and largeâ€fiber neuropathy related to hypereosinophilic syndrome. Clinical and Experimental Neuroimmunology, 0, , .	0.5	0
102	Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.. Blood, 2005, 106, 4670-4670.	0.6	0
103	Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation.. Blood, 2007, 110, 3468-3468.	0.6	0
104	Incidence of Febrile Episode During Stem Cell Mobilization (SCM) After High Dose Ciclophosphamide Chemotherapy (HD-CTX) and G-CSF (filgrastim or lenograstim) Administration in Multiple Myeloma (MM) Patients: II Interim Evaluation. Blood, 2008, 112, 4135-4135.	0.6	0
105	Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis.. Blood, 2009, 114, 4772-4772.	0.6	0
106	Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis.. Blood, 2009, 114, 3945-3945.	0.6	0
107	Incidence of Febrile Episodes During Stem Cells Mobilization After High Dose Cyclophosphamide Chemotherapy and G-CSF (filgrastim or lenograstim) Administration in Multiple Myeloma Patients: Preliminary Final Results.. Blood, 2009, 114, 4560-4560.	0.6	0
108	Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.. Blood, 2009, 114, 1723-1723.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Age-Dependent Influence of TNF-Î± Polymorphism on Progression Free Survival of ASCT In Multiple Myeloma Patients. Blood, 2010, 116, 1829-1829.	0.6	0
110	Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients. Blood, 2010, 116, 5033-5033.	0.6	0
111	Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium. Blood, 2011, 118, 5014-5014.	0.6	0
112	Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis.. Blood, 2012, 120, 2929-2929.	0.6	0
113	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. Blood, 2013, 122, 2659-2659.	0.6	0
114	CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD. Blood, 2015, 126, 1768-1768.	0.6	0
115	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaÏŠVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. Blood, 2016, 128, 1230-1230.	0.6	0